Literature DB >> 18703394

[Epithelial-mesenchymal transition of the renal graft].

A Hertig1.   

Abstract

About 40 % of renal graft losses over 10 years in Europe are caused by fibrosis. To explain the origin of interstitial fibroblasts, the epithelial-mesenchymal transition (EMT) theory has been recently ventured : under the effect of an aggression, tubular epithelial cells may change into fibroblasts, cross over the basal membrane, and join interstitium. This innovative hypothesis has been confirmed by the finding of a "fibroblast-specific" protein FSP-1 in the tubular epithelium, then by the detection of fibroblast-like FSP-1 expressing cells in the proximal tubule by confocal microscopy in a transgenic murine model in which fibrosis has been induced. In the renal graft, EMT markers such as FSP-1 and vimentin, have been detected in tubular epithelium in case of chronic allograft nephropathy, correlatively to the loss of expression of epithelial markers. The expression of EMT markers takes place very early, in the first months post-transplantation, in transplant patients whose renal function is not yet impaired, suggesting the existence of a patho-physiological link between EMT markers expression and graft fibrosis development.

Entities:  

Mesh:

Year:  2008        PMID: 18703394     DOI: 10.1016/S1769-7255(08)73648-4

Source DB:  PubMed          Journal:  Nephrol Ther        ISSN: 1769-7255            Impact factor:   0.722


  2 in total

Review 1.  Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases.

Authors:  Hong Zhao; Yanting Dong; Xinrui Tian; Thian Kui Tan; Zhuola Liu; Ye Zhao; Yun Zhang; David Ch Harris; Guoping Zheng
Journal:  World J Nephrol       Date:  2013-08-06

2.  A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.

Authors:  Yuanmeng Jin; Krishna Ratnam; Peter Y Chuang; Ying Fan; Yifei Zhong; Yan Dai; Amin R Mazloom; Edward Y Chen; Vivette D'Agati; Huabao Xiong; Michael J Ross; Nan Chen; Avi Ma'ayan; John Cijiang He
Journal:  Nat Med       Date:  2012-03-11       Impact factor: 53.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.